Comparison of a Novel Commercial Immunoassay, AGILE Research, and the Meso Scale Discovery Array System for the Quantification of Insulin and Leptin in Human Plasma

Abstract

Protein quantification for the purpose of diagnosis or monitoring of disease and disease states are integral to patient care. However, modern immunoassays tend to rely on indirect assays to provide quantitative measurements of target molecules, which increase the complexity of the assay and can introduce error into the results. For example, the Meso Scale Discovery (MSD) Insulin and Leptin Single Array kits use a sandwich immunoassay and an electrochemiluminescent response to measure analyte concentrations in serum or plasma samples. We present measurements determined using a novel direct detection approach that leverages advances in nanoelectronic sensors to obtaining quantification of protein concentrations in complex human samples. AGILE Research is a new, commercially available tool using graphene biological field effect transistors that eliminates the need for secondary labeled antibodies to obtain results. We present data from use of these tools in comparison to data collected using the MSD Insulin and Leptin Single Array assay.